David A. Siegel Silence Therapeutics PLC Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 83,300 shares of SLN stock, worth $577,269. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,300
Previous 76,200
9.32%
Holding current value
$577,269
Previous $1.45 Million
4.7%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SLN
# of Institutions
71Shares Held
28.1MCall Options Held
300Put Options Held
2K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$21 Million7.16% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$19.6 Million2.57% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY2.66MShares$18.5 Million3.3% of portfolio
-
Redmile Group, LLC San Francisco, CA1.9MShares$13.2 Million2.26% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.15MShares$7.96 Million1.12% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $249M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...